Immatics N.V. IMTX 深 沪
等待开盘 07-02 09:30:00 美东时间
9.85
-0.280
-2.76%
华盛通- 最 高10.19
- 今 开10.04
- 成交量 27.04万股
- 最 低 9.78
- 昨 收 10.13
- 总市值 13.46亿
- 52周最高 12.41
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 5.05
- 委 比 -93.99%
- 总股本 1.37亿
- 历史最高 18.42
- 量 比 0.59
- 振 幅 4.05%
- 历史最低 3.30
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy, showing significant anti-tumor activity in platinum-resistant ovarian cancer and uterine cancer with a 63% objective response rate (ORR) and 50% confirmed ORR (cORR), including four complete responses. In heavily pretreated patients with synovial sarcoma, the therapy demonstrated a 67% ORR and 64% cORR, with responses lasting up to ~3 years. IMA203CD8 exhibit...
05-30 12:00
Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) by 19.05 percent. This is a 42.86 percent decrease over losses of $(0.35) per share from the
05-12 19:29
TD Cowen Initiates Coverage On Immatics with Buy Rating
TD Cowen analyst Nicholas Lorusso initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating.
04-28 23:59
Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026
Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced that an abstract
04-18 03:08
Immatics Earnings Report: Q4 Overview
The Q4 earnings report for Immatics (NASDAQ:IMTX) was released on Thursday, Mar...
03-05 20:14
Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. This is a 170.83 percent decrease over earnings of $0.48 per share from the
03-05 20:12
Immatics Unveils IMA203CD8 Phase 1a Findings Demonstrating Durable Responses And Tumor-Agnostic Potential In PRAME-Expressing Cancers
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced
2025-12-11 20:11
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
Immatics To Raise $125M Through Sale of 12.5M Shares at $10 Each
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary
2025-12-05 19:05
